Consider investing in Hims & Hers Health (HIMS), as the market appears to be misinterpreting its growth guidance. The company's official forecast excludes the upcoming Eucalyptus acquisition, which could add an unpriced $200 million in revenue and represent a significant near-term catalyst. The weight loss business is also more resilient than perceived due to its profitable oral medications, reducing reliance on the legally challenged GLP-1 market. For long-term growth in the pharmaceutical space, look at Eli Lilly (LLY), whose pipeline drug retatrutide is considered a potential blockbuster that could lead the next generation of weight loss treatments. The ultimate bull case for HIMS is its long-term potential to become a dominant, AI-driven direct-to-consumer healthcare platform.

Hims & Hers Health, Inc. (HIMS)

• Bullish Sentiment: The speaker is extremely bullish on HIMS, arguing that the market and social media are misinterpreting the company's recent earnings report and guidance, creating what he calls "FUD" (Fear, Uncertainty, and Doubt).
• Misunderstood Guidance: A key point of contention is the company's growth guidance. The speaker emphasizes that the official guidance excludes the upcoming acquisition of Eucalyptus.
  • The guidance, when factoring in the potential $200 million in revenue from Eucalyptus, could represent 24% to 33% year-over-year growth, not the low single-digit growth some critics are claiming.
• Weight Loss Business: The market is incorrectly conflating HIMS's entire weight loss business with just GLP-1s.
  • The weight loss category reached a $100 million revenue run rate in under seven months, excluding contributions from compounded GLP-1s.
  • A significant and profitable part of the business is selling oral weight loss medications like metformin and bupropion, which are prescribed "off-label".
  • Many customers who initially inquire about expensive GLP-1s end up choosing these more affordable oral options.
• GLP-1 Lawsuit Risk: The lawsuit from Novo Nordisk over compounded semaglutide is presented as a manageable, long-term risk.
  • The legal timeline is very long, with a potential resolution not expected until 2029-2031.
  • The speaker believes semaglutide may become obsolete in the U.S. once newer drugs like retatrutide from Eli Lilly are approved, potentially making the lawsuit less relevant over time.
• Disruptive Business Model: HIMS is framed as a customer-centric company, similar to Amazon, that is disrupting the "legacy healthcare" system.
  • It achieves this through transparent, bundled pricing (doctor visit + prescription), convenience, and better privacy than traditional pharmacies.
  • This disruptive nature is cited as a reason why "Wall Street hates it with a passion."
• Future Growth Catalysts (The AI & Data Thesis): The long-term bull case is heavily tied to technology and data.
  • Data Collection: HIMS is building a massive, uniform dataset from its 2.5 million+ customers, which is seen as extremely valuable for developing future AI applications.
  • AI Applications: The speaker envisions HIMS using AI for diagnostics, AI-designed compounded medications (via its MedMatch recommender system), predictive health simulations, and even "digital twins" for testing drug efficacy.
  • New Technologies: Future growth is also expected from at-home lab testing (via the Tribe acquisition and its "painless needle"), wristband trackers, and mouth swab tests.

Takeaways

• Investors should look beyond the headline guidance numbers, as the Eucalyptus acquisition could provide a significant, unpriced catalyst for revenue growth in the near future.
• The company's weight loss segment appears more resilient than perceived due to its diversified offering of profitable oral medications, reducing its sole reliance on the legally contentious GLP-1 market.
• The long-term investment thesis for HIMS is not just about selling pills online; it's a bet on the company becoming a dominant AI-driven, direct-to-consumer healthcare platform. This represents a high-growth but also high-risk opportunity.
• The ongoing lawsuit is a risk factor, but its impact may be diminished by the long legal timeline and evolving market dynamics in weight loss drugs.

Eli Lilly and Company (LLY)

• Retatrutide as a "Miracle Drug": The speaker is extremely optimistic about Lilly's pipeline drug, retatrutide.
  • He describes it as a potential "miracle drug" and "blockbuster" that could be superior to current GLP-1s like semaglutide.
  • The speaker believes it's worth analyzing LLY stock just on the potential of this single drug.
• Potential Partnership with HIMS: A speculative but interesting point is the potential for a future partnership between Lilly and HIMS.
  • The speaker notes that HIMS has deliberately avoided conflict with Lilly by never compounding its drug, tirzepatide.
  • He points to the fact that Lilly's Chief Medical Officer is now following HIMS on social media as a possible sign of a non-confrontational relationship that could lead to collaboration once retatrutide is approved.

Takeaways

• Eli Lilly's future growth may be significantly driven by its next-generation weight loss drug, retatrutide, which is viewed as a potential market leader.
• A speculative upside for Lilly could be a future distribution partnership with a direct-to-consumer platform like HIMS, which would grant it immediate access to millions of potential customers.

LifeMD (LFMD)

• Market Corroboration: LifeMD is mentioned as a point of comparison that validates a key trend in the telehealth market.
• The speaker notes that LifeMD has also publicly stated that many of its customers switch from inquiring about expensive GLP-1s to purchasing more affordable oral weight loss medications.

Takeaways

• The trend of patients opting for cheaper, oral weight loss alternatives over injectable GLP-1s is a broader market dynamic, not just a HIMS-specific phenomenon. This could be a positive indicator for other telehealth companies like LifeMD that offer similar diversified weight loss programs.